HIV-1型核衣壳蛋白P24截短体在大肠杆菌中的表达,纯化和鉴定

用聚合酶链式反应（ＰＣＲ）从ＨＩＶ １ｇａｇ基因中扩增出衣壳蛋白Ｐ２４截短体（ｔＰ２４）基因,插入质粒ｐＧＥＸ ４Ｔ３中构成重组表达质粒ｐＧＥＸ ｔｐ２４,将ｐＧＥＸ ｔｐ２４转化大肠杆菌ＢＬ２１后获得了高效表达,表达量占菌体总蛋白量的３４３８％。经Ｇｌｕｔａｔｈｉｏｎｅ－Ｓｅｐｈａｒｏｓｅ４Ｂ亲和层析纯化的截短体Ｐ２４纯度为９２７７％。纯化的截短体Ｐ２４在间接ＥＬＩＳＡ和免疫印迹检测ＨＩＶ抗体阳性血清和正常人血清中,具有很高的抗原特异性和免疫反应性。     

HIV—1 p24蛋白在大肠肝菌中的高效可溶性表达,一步纯化抗原性分析

合成引物扩增ＨＩＶ－１ ｐ２４基因,并将其克隆到ｐＱＥ－３０质粒中,使其在大肠杆菌Ｅ．ｃｏｌｉ Ｍ１５中以ＩＰＴＧＨ诱导高效它ＳＤＳ－ＰＡＧＥ分析,该表达产物约占菌体总蛋白２０％,并且以可溶蛋白的形式存在于细菌裂解液上清之中。经镍离子柱亲和层一步纯化,洗脱产物中ｐ２４蛋白纯度达９５％。ＥＬＩＳＡ分析表明,该蛋白可与ＨＩＶ感染者血肖发生物异改正 免疫反应。以此蛋白交联Ｓｅｐｈａｒｏｓｅ ４Ｂ,新和层     

HIV—1Gag蛋白在大肠杆菌和重组杆状病毒系统中的高效表达及通用型 …

将中国株ＨＩＶ－１Ｂ亚型ｇａｇ全基因序列,克隆杆状病毒表达载体ｐｆａｓｔｂａｃＩ中,构建了重组质粒ｐｆａｓｔＧａｇ,利用细菌／杆状病毒表达和筛选重组杆状病毒,在昆虫细胞中高效表达ＨＩＶ－１Ｇａｇ蛋白。通过改造原核表达载体ｐＢＶ２２０和ｐＥＴ２８,构建了一种新的通用型温控原核表达载体质粒ｐＶＶ５,该载体携带ＰｒＰｌ串联温控启动子及Ｈｉｓ－Ｔａｇ纯化标签,利于目的的蛋白表达与纯化。     

小鼠PC-1基因在大肠杆菌中的表达和纯化

利用PCR和基因重组技术构建了小嫌PC－1基因全长cDNA及其N端45个氨基酸残基的表达质粒pGEX-4T-1-mPC-1和pGEX-4T-1-mPC-1-45。经IPTG诱导后,在大肠杆菌DH5α中,GST－mPC-1和GST－mPC-1-45两个融合蛋白都获得了可溶性高表达。经谷胱甘肽Sepharose-4B亲和柱层析纯化后,获得了纯的GST－mPC-1和GST－mPC-1-45蛋白。     

HIV-1 CRF07 B/C亚型gp41的表达、纯化和初步结构分析

HIV-1跨膜蛋白gp41是HIV-1包膜与靶细胞膜融合过程中的关键蛋白,而且序列保守,是理想的HIV-1作用靶点。为获得HIV-1中国流行株CRF07 B/C gp41蛋白的晶体结构来指导疫苗设计及药物开发,采用CRF07 B/C gp160基因序列为模板,经PCR、酶切、连接,将gp41 helix-bundle区域克隆到pET30-his表达载体中,经表达、纯化和结晶筛选,获得了gp41 helix-bundle的晶体并解析了结构,为针对中国艾滋病病毒流行株疫苗的设计及药物开发提供了结构参考。     

重组HIV—1逆转录酶的纯化与活性研究

利用高效重组表达载体ＲＰ６６工程菌诱导发酵产生无活性的包体形式重组ＨＩＶ－１逆转录酶,经过一定条件的摸索,确定了包涵体形ＲＴ蛋白洗涤、增溶、复性的条件。复性后的可溶性蛋白,经疏水相互作用和阴离子交换层析进一步分离纯化。     

新型载体蛋白P64K在大肠杆菌中的可溶性表达与纯化

用常规PCR方法从脑膜炎球菌中克隆出P64K基因,构建重组质粒pET28a-P64K转化BL21(DE3)宿主菌,经眦诱导表达筛选P64K蛋白的高表达菌株。结果证实P64K蛋白为胞内可溶性表达,表达量约占胞内总蛋白的30％。重组P64K蛋白经Butyl疏水柱、G200分子筛柱和Q阴离子柱三步层析后纯度达到95％以上,为今后进一步的功能和应用研究打下了良好的基础。     

HIV—1gp41基因的高效表达及表达产物的纯化

为了获得高效表达的人类免疫缺陷病毒（ＨＩＶ１）ｇｐ４１蛋白,从而为ＨＩＶ１基因工程诊断抗原的国产化打下基础,用ＰＣＲ的方法从ＨＩＶ１全基因序列中扩增出编码ｇｐ４１Ｎ端的６９０ｂｐ片段。经酶切后,克隆到ｐＥＴ２８ａ载体中,再将重组质粒转化到表达宿主菌ＢＬ２１（ＤＥ３）中,经ＩＰＴＧ诱导,高效表达出ｇｐ４１蛋白。间接ＥＬＩＳＡ、Ｗｅｓｔｅｒｎｂｌｏｔ、ＳＤＳＰＡＧＥ电泳证实,该表达产物具有良好的抗原性和特异性,且表达量约占总菌体蛋白的４５％。重组蛋白经金属鏊合纯化,纯度达９９％。     

HIV—1外膜蛋白在甲醇型醇母Pichia pastoris中的表达与鉴定

为建立用甲醇型酵母Pichia pastoris表达HIV－2Rod gp105的新途径,用PCR方法获得HIV－2Rod gp105基因,并将其克隆到P.Pastoris分泌型表达载体pHILS1中,测序正确后将重组质粒pHILS1-gp105电转化GS115。用PCR法筛选阳性P.Pastoris重组子,并用甲醇诱导表达,SDS－PAGE和Western印迹结果表明,与HIV－1不同,HIV－2的外膜蛋白gp105能在甲醇型酵母Pichia Pastori中诱导表达,产物为－90kD的糖蛋白,具有良好的抗原特异性。     

EB病毒融合蛋白Zta-P54在大肠杆菌中的表达、纯化及鉴定

为获得能用于检测试剂盒的高纯度具有活性的EB病毒融合蛋白,以pGEX5T-BZLF1-BMRF1质粒为模板进行PCR扩增得到BZLF1-BMRF1融合基因,将其插入pET32a中,构建表达质粒pET32a/BZLF1-BMRF1。将该质粒转入大肠杆菌培养,经IPTG诱导获得Zta-P54融合蛋白。用DEAE-Sepharose CL-6B和Ni-NTA亲和层析纯化,并通过SDS-PAGE和Western blot对Zta-P54融合蛋白进行鉴定。双酶切鉴定和测序结果显示成功构建pET32a/BZLF1-BMRF1质粒,SDS-PAGE显示该蛋白相对分子量约为60kD,与预期结果一致。纯化后获得纯度为96.5%的Zta-P54融合蛋白。Western blot检测该蛋白有良好的生物活性和反应特异性。因此,成功构建pET32a/BZLF1-BMRF1质粒,在大肠杆菌中可溶性表达。最终获得纯度高、生物活性好的融合蛋白。     

Expression, purification, and characterization of recombinant human interleukin 24 in Escherichia coli

Interleukin-24 (IL-24) can induce apoptosis of a broad range of tumor cells, and this function of IL-24 is independent of classic tumor suppressor genes, such as p53, Rb and p16. Here, we report the expression, purification and preparation of a recombinant IL-24 protein (rIL-24) without post-translational modifications, which may selectively induce apoptosis of tumor cells in vitro. We found that non-fusion rIL-24 was not able to be expressed by vectors pET11c, 28a, and 22b in Escherichia coli. To obtain recombinant non-fusion IL-24 protein, the encoding region for IL-24 was cloned between KpnI and BamHI in pET32a. The Trx (Thioredoxin)/IL-24 fusion proteins were expressed in the form of inclusion bodies in E. coli host strain BL21 (DE21). The expression level was more than 30% of total cell lysate. Inclusion bodies were disrupted, washed, and isolated at pH 9.0, and were completely dissolved in a buffer containing 2M urea at pH 9.0. After nickel ion metal affinity chromatography, gel filtration chromatography, and renaturation, the refolded fusion proteins with a purity of >96% were obtained. Trx/IL-24 proteins were digested by enterokinase (EK) to both Trx and rIL-24 fragments which then were separated by cation exchange chromatography. Cell proliferation experiments proved that the rIL-24 (98% purity) retains its cancer-selective apoptosis-inducing properties. This result suggested that the rIL-24 may have cancer therapeutic applications.     

Expression and purification of human respiratory syncytial virus recombinant fusion protein

The Human Respiratory Syncytial Virus (HRSV) fusion protein (F) was expressed in Escherichia coli BL21A using the pET28a vector at 37 °C. The protein was purified from the soluble fraction using affinity resin. The structural quality of the recombinant fusion protein and the estimation of its secondary structure were obtained by circular dichroism. Structural models of the fusion protein presented 46% of the helices in agreement with the spectra by circular dichroism analysis. There are only few studies that succeeded in expressing the HRSV fusion protein in bacteria. This is a report on human fusion protein expression in E. coli and structure analysis, representing a step forward in the development of fusion protein F inhibitors and the production of antibodies.     

The extracellular domain of immunodeficiency virus gp41 protein: expression in Escherichia coli, purification, and crystallization.

The env gene of SIV and HIV-1 encodes a single glycoprotein gp 160, which is processed to give a noncovalent complex of the soluble glycoprotein gp120 and the transmembrane glycoprotein gp41. The extracellular region (ectodomain), minus the N-terminal fusion peptide, of gp41 from HIV-1 (residues 27-154) and SIV (residues 27-149) have been expressed in Escherichia coli. These insoluble proteins were solubilized and subjected to a simple purification and folding scheme, which results in high yields of soluble protein. Purified proteins have a trimeric subunit composition and high alpha-helical content, consistent with the predicted coil-coil structure. SIV gp41 containing a double cysteine mutation was crystallized. The crystals are suitable for X-ray structure determination and, preliminary analysis, together with additional biochemical evidence, indicates that the gp41 trimer is arranged as a parallel bundle with threefold symmetry.     

Characterization of monoclonal antibodies to human immunodefiency virus type 1 gp41 by HIV-1 polypeptides expressed in Escherichia coli

Abstract Two monoclonal antibodies (MAbs) were produced in Balb/c mice by immunization with recombinant gp41 derived from expression of λ-BH10 cDNA of the human immunowdeficiency virus-1 (HIV-1) in the prokaryotic expression vector pEX-41 [1, 2]. Characterization of the epitopes recognized by these MAbs was done with HIV-1 envelope (env) fusion proteins expressed in Escherochia coli encoding ten distinct segments of the env proteins [3]. In comparison, another mouse MAb, M25 [4], a human MAb directed against gp41, which was produced by the xeno hydridoma line 3D6 [5, 6] and a pool of human patient sera containing antibodies to HIV-1 were tested. We were able to demonstrate that the epitopes recognized by our MAbs are located betweeni arg732 and ser759 [7] of the HIV-1 env glycoprotein gp160 of HTLV-III strain B. M25 reacted with epitopes between ser647 and pro731, which includes the hydrophobic transmembrane region of gp41 [4]. The human MAb against gp41, 3D6 [5, 6] reacts with epitopes between ile474 and trp646, a polypeptide stretch consisting of gp120 and gp41 specific amino acids. The human serum pool, positive for HIV-1 antibodies, reacted predominantly with antigenic determinants locatedp between ile474 and leu863. The recombinant env fusion proteins were initially produced to test the immunoreactivity with patient sera and to characterize epitopes which are relevant for immunodiagnostic purposes [3]. In this study, we showed that the set of recombinant evr proteins is also a simple and accurate tool for the characterization of MAbs directed to the HIV envelope proteins.     

融和蛋白GST-SUMO-MT在大肠杆菌中的表达、纯化及其活性研究

将编码融合蛋白GST-SUMO-MT的DNA片段连接到大肠杆菌表达载体pET-28a中,构建重组表达质粒pET-GS-MT并转化到大肠杆菌Origami（DE3）中。20℃,1mM的IPTG诱导20h后,获得分子量约为43Kd的融合蛋白,表达量占菌体上清总蛋白的38.4％。利用谷胱甘肽交联琼脂糖（Glutathione Sepharose 4B）凝胶柱和Sephardex G-25分子筛联用可以得到纯度为95%以上的融合蛋白,得率约为70mg/L。该融合蛋白可与GST抗体产生阳性反应。融合蛋白GST-SUMO-MT可以显著提高宿主对Cd2+、Zn2+和Cu2+离子聚积的能力,其耐受能力比对照组分别提高4.2倍、4倍及1.6倍。此外,原子吸收光谱法测定,每分子GST-SUMO-MT可以结合2-3个Cd2+离子。     

在大肠杆菌中高效表达人类免疫缺陷病毒Ⅰ型(HIV-1)核心蛋白

将编码人类免疫缺陷病毒Ⅰ型(HIV-1)核心蛋白(Gag)P24的大部分基因片段,插入大肠杆菌表达载体pEX31A中,获得的表达产物MS2-Gag融合蛋白占菌体总蛋白的20％左右。Western blot结果证明,这种表达产物能被艾滋病(AIDS)患者血清中的特异性抗体所识别。这是国内首次报道在大肠杆菌中高效表达人类免疫缺陷病毒Ⅰ型核心蛋白。对表达的重组核心蛋白的意义及应用前景进行了讨论。     

人类免疫缺陷病毒Ⅰ型Gag前体蛋白片段在大肠杆菌中的表达、纯化及鉴定

利用新型原核表达载体pDOG,在大肠杆菌中高效表达了人类免疫缺陷病毒1型(HIV-1)gag基因片段。表达载体利用λPR启动子以及T7g-10的RBS来有效起始表达基因的翻译。表达片段PG1包括p17C-端13个氨基酸、整个p24以及p15N-端74个氨基酸。与PG1相比,PG2片段不含有p17序列,并缺失了p24N-端77个氨基酸。两者的表达量均占总菌体蛋白的20％以上。重组蛋白以包涵体形式存在,在提取包涵体后,经过一步离子柱层析,可以纯化到90％以上的纯度。PG1可被一株抗p24的单抗特异识别,而PG2则不能。纯化的重组蛋白能与HIV-1阳性血清发生很强的特异反应,可以用于HIV-1抗体检测中。     

蛇毒锯鳞蝰素融合蛋白的发酵与纯化

研究大肠杆菌表达重组蛇毒锯鳞蝰素(Echistatin,Ecs)融合蛋白的发酵和纯化工艺。将Ecs基因插入表达载体pTXB1,转化E.coliBL21(DE3)构建工程菌。对工程菌进行补料分批培养并诱导表达,研究培养基、培养和诱导时间对工程菌生长和目的蛋白表达的影响,几丁质亲和层析纯化Ecs融合蛋白,经DTT裂解后,检测Ecs活性。发酵后菌体湿重可达75g/L,融合蛋白表达量约占总蛋白的35%,重组质粒在BL21宿主菌中传代稳定。亲和层析纯化后,得到Ecs单体,得率为28mg/L发酵液。生物学活性分析显示,重组Ecs能有效抑制血小板的聚集,其活性与天然Ecs相似。优化了Ecs融合基因工程菌的发酵和纯化条件,为规模化生产奠定基础。